Pharmaceutical - Pharmaceutical

Filter

Current filters:

Pharmaceutical

Popular Filters

1 to 25 of 7175 results

Portola’s andexanet alfa reverses Eliquis anticoagulant effect

17-12-2014

A Phase III clinical trial has found that Portola Pharmaceuticals' (Nasdaq: PTLA) andexanet alfa reverses…

andexanet alfaBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPortola PharmaceuticalsResearch

Strong top-line results for Poxel’s antidiabetic agent imeglimin

17-12-2014

France-based drug developer Poxel says that imeglimin, a novel compound in development to treat type…

DiabetesHealthimegliminMerck SeronoPharmaceuticalPoxelResearch

KCR acquires project portfolio from Ukraine’s CRO AXIS

KCR acquires project portfolio from Ukraine’s CRO AXIS

17-12-2014

KCR, a Poland-based contract research organization (CRO), has recently acquired the whole portfolio of…

AXIS GroupKCRMergers & AcquisitionsPharmaceuticalResearchUkraine

Ipsen appoints François Garnier as executive vice president, general counsel

Ipsen appoints François Garnier as executive vice president, general counsel

17-12-2014

French drugmaker Ipsen has appointed François Garnier as executive vice president, general counsel of…

BoardroomFranceIpsenIpsen GroupPharmaceutical

New guidance provides optimism for securing life sciences patents in USA

New guidance provides optimism for securing life sciences patents in USA

17-12-2014

The US Patent and Trademark Office (USPTO) has released its 2014 Interim Guidance on Patent Subject Matter…

PatentsPharmaceuticalPrometheus LabsUS Patent and Trademark OfficeUSA

FDA approves Ipsen's Somatuline for metastatic gastroentero pancreatic neuroendocrine tumors

FDA approves Ipsen's Somatuline for metastatic gastroentero pancreatic neuroendocrine tumors

17-12-2014

The US Food and Drug Administration has approved Somatuline Depot (lanreotide) injection 120mg, manufactured…

IpsenOncologyPharmaceuticalRegulationSomatulineUSA

Top 30 Pharmas spent $112 billion on R&D in 2013; report

Top 30 Pharmas spent $112 billion on R&D in 2013; report

17-12-2014

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development…

FinancialGlobalGlobalDataJohnson & JohnsonNovartisPfizerPharmaceuticalPharmaceutical sciencesResearch

Janssen returns rights of IBD drug GLPG1205 to Galapagos

Janssen returns rights of IBD drug GLPG1205 to Galapagos

17-12-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has returned the rights to…

GalapagosGastro-intestinalsJanssenJanssen PharmaceuticaLicensingPharmaceutical

Cyclacel shares fall as sapacitabine disappoints in Phase III acute myeloid leukemia trial

Cyclacel shares fall as sapacitabine disappoints in Phase III acute myeloid leukemia trial

17-12-2014

The announcement that Cyclacel Pharmaceuticals’ (Nasdaq: CYCC) Phase III trial of sapacitabine was…

CyclacelOncologyPharmaceuticalResearchsapacitabine

New drug price cuts demonstrate Australian PBS sustainability

New drug price cuts demonstrate Australian PBS sustainability

17-12-2014

In Australia, price cuts to over 100 Pharmaceutical Benefits Scheme (PBS)-listed medicines that will…

AustraliaAustralian PBSHealthcarePharmaceuticalPricing

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

17-12-2014

In final guidance published today, UK health cost watchdog the National Institute for Health and Care…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

Lightlake in deal with Adapt Pharma subsidiary

16-12-2014

UK biopharma firm Lightlake Therapeutics has entered into a license agreement with Adapt Pharma Operations,…

Adapt PharmaLicensingLightlake TherapeuticsNaloxoneNeurologicalPharmaceutical

Trade groups call for integrated life science strategy ahead of European Commission Work Program

Trade groups call for integrated life science strategy ahead of European Commission Work Program

16-12-2014

European research and generic/biosimilar industry associatins have called for an integrated life science…

Advocacy groupsCompetitivenessEuropePharmaceuticalRegulation

Novartis gains US FDA approval of Signifor for acromegaly

Novartis gains US FDA approval of Signifor for acromegaly

16-12-2014

The US Food and Drug Administration has approved Swiss pharma giant Novartis’ Signifor (pasireotide)…

NovartisPharmaceuticalRare diseasesRegulationSigniforUSA

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

16-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued new…

InlytaOncologyPfizerPharmaceuticalPricingRegulationUK

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

16-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has compared trial data on German…

BayerEyleaGermanyLucentisNovartisOphthalmicsPharmaceuticalPricingRegulationRoche

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

15-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) have recommended…

BayerOncologyPharmaceuticalPricingRegulationUKXofigo

OPKO Health leaps on potential $570 million deal with Pfizer

OPKO Health leaps on potential $570 million deal with Pfizer

15-12-2014

US drugmaker OPKO Health saw its shares leap 13.8% in pre-market trading, when it revealed a licensing…

LicensingOPKO HealthPfizerPharmaceuticalRare diseasesUSA

Immune Pharmaceuticals appoints Daniel Kazado chairman of the board

Immune Pharmaceuticals appoints Daniel Kazado chairman of the board

15-12-2014

US-Israeli company Immune Pharmaceuticals has appointed Daniel Kazado chairman of the board, succeeding…

BoardroomImmune PharmaceuticalsIsraelPharmaceuticalUSA

Spain’s Supreme Court opines on Pfizer dual pricing contracts

Spain’s Supreme Court opines on Pfizer dual pricing contracts

15-12-2014

The Spanish Supreme Court has reviewed a ruling adopted by the Audiencia Nacional, itself annulling a…

EuropeLegalPfizerPharmaceuticalPricingSpain

Novartis' Cosentyx demonstrates superiority to Stelara in head-to-head psoriasis study

Novartis' Cosentyx demonstrates superiority to Stelara in head-to-head psoriasis study

15-12-2014

Swiss drug major Novartis announced that the Phase IIIb CLEAR study for Cosentyx (secukinumab) met its…

CosentyxDermatologicalsNovartisPharmaceuticalResearchSwitzerland

Novartis' Afinitor trial does not demonstrate statistical significance in HER2-positive breast cancer

Novartis' Afinitor trial does not demonstrate statistical significance in HER2-positive breast cancer

15-12-2014

Novartis announced that its BOLERO-1 trial of Afinitor (everolimus) in combination with Herceptin (trastuzumab)…

AfinitorHerceptinNovartisNovartis OncologyOncologyPaclitaxelPharmaceuticalResearchSwitzerland

India’s National Pharmaceutical Pricing Authority caps price of 52 more drugs

India’s National Pharmaceutical Pricing Authority caps price of 52 more drugs

15-12-2014

The National Pharmaceutical Pricing Authority (NPPA) of India has issued a notice capping prices of 52…

BaxterGlaxoSmithKlineIndiaPharmaceuticalPricingRegulationWockhardt

1 to 25 of 7175 results

Back to top